NISPC Reinstates Paper and Pencil Exams
Alexandria, Virginia — The National Institute for Standards in Pharmacist Credentialing (NISPC) will reinstate the paper and pencil disease state management (DSM) credentialing exams in anticoagulation, asthma, and diabetes beginning at the 2001 National Community Pharmacists Association (NCPA) Annual Convention in Philadelphia, Pennsylvania. NCPA’s Convention will be held October 13 through 17. Test dates are October 15 and 16.
The exams will be offered in a paper and pencil format three times during the course of the convention. Licensed pharmacists in good standing with their respective state boards of pharmacy are eligible to take the exam. Two years of practice experience are recommended. Pharmacists who are interested in taking one or more of the DSM exams may request an application or additional information by contacting NISPC by fax at (703) 683-3619 Attention: NISPC, or by phone at (703) 299-8790.
Future paper and pencil offerings are being planned. Currently on the slate is the American Pharmaceutical Association (APhA) Annual Meeting in Philadelphia, Pennsylvania, in March 2002. NISPC will continue to pursue additional paper and paper exam offerings.
In addition, the NISPC DSM exams are still being offered in a computerized format. With over 250 testing sites nationwide, pharmacists can register to take the computerized version of any of the three (3) DSM exams virtually any time of the year at their convenience. Call the NISPC Testing Center at (847) 698-6227 for more information regarding the computerized NISPC exams.
NISPC was formed in 1998 by the American Pharmaceutical Association (APhA), the National Association of Boards of Pharmacy (NABP), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) to create a consolidated, nationally-recognized, disease state management credential for pharmacists. Since 1998, NISPC has credentialed nearly 1,000 pharmacists nationally in anticoagulation, asthma, diabetes, and dyslipidemia.